Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study

被引:20
作者
Falk, GW
Skacel, M
Gramlich, TL
Casey, G
Goldblum, JR
Tubbs, RR
机构
[1] Cleveland Clin Fdn, Dept Gastroenterol & Hepatol, Ctr Swallowing & Esophageal Disorders, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Clin Pathol, Ctr Swallowing & Esophageal Disorders, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Dept Anat Pathol, Ctr Swallowing & Esophageal Disorders, Cleveland, OH 44195 USA
[4] Cleveland Clin Fdn, Dept Canc Biol, Ctr Swallowing & Esophageal Disorders, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0016-5107(04)01687-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Endoscopic brush cytology is a promising surveillance technique for Barrett's esophagus. However, there is a need for ancillary biomarkers to increase the sensitivity of cytology and to allow identification of patients at increased risk for disease progression. The aims of this study were to evaluate the feasibility of fluorescence in situ hybridization of endoscopic brush cytology specimens and to determine if there are specific chromosomal changes in cytologic specimens from patients with cancer that are not present in patients without dysplasia. Methods: Archival cytology slides from 16 patients with Barrett's esophagus were studied: 8 negative for dysplasia and 8 positive for adenocarcinoma. Fluorescence in situ hybridization was used to detect two alterations: HER-2 gene (17q11.2-q12) and 20q13.2 region amplification. Observations: For 7 of 8 adenocarcinoma cases, there was amplification/aneusomy of at least one of the two analyzed regions by fluorescence in situ hybridization. None of the samples negative for dysplasia were abnormal for either of the two genomic regions studied. Conclusions: Fluorescence in situ hybridization is feasible by using routine Barrett's esophagus cytologic specimens. Differences in genomic makeup can be detected in cells from patients negative for dysplasia and in those with adenocarcinoma.
引用
收藏
页码:280 / 284
页数:5
相关论文
共 43 条
  • [1] Barrett MT, 1996, ONCOGENE, V13, P1867
  • [2] p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus
    Bian, YS
    Osterheld, MC
    Fontolliet, C
    Bosman, FT
    Benhattar, J
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : 1113 - 1121
  • [3] HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma
    Brien, TP
    Odze, RD
    Sheehan, CE
    McKenna, BJ
    Ross, JS
    [J]. HUMAN PATHOLOGY, 2000, 31 (01) : 35 - 39
  • [4] Dar M, 2002, GASTROINTEST ENDOSC, V55, pAB200
  • [5] Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus
    Doak, SH
    Jenkins, GJS
    Parry, EM
    D'Souza, FR
    Griffiths, AP
    Toffazal, N
    Shah, V
    Baxter, JN
    Parry, JM
    [J]. GUT, 2003, 52 (05) : 623 - 628
  • [6] Falk Gary W, 2003, Gastrointest Endosc Clin N Am, V13, P335, DOI 10.1016/S1052-5157(03)00016-3
  • [7] Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia
    Falk, GW
    Rice, TW
    Goldblum, JR
    Richter, JE
    [J]. GASTROINTESTINAL ENDOSCOPY, 1999, 49 (02) : 170 - 176
  • [8] Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology
    Falk, GW
    Chittajallu, R
    Goldblum, JR
    Biscotti, CV
    Geisinger, KR
    Petras, RE
    Birgisson, S
    Rice, TW
    Richter, JE
    [J]. GASTROENTEROLOGY, 1997, 112 (06) : 1787 - 1797
  • [9] Practice patterns for surveillance of Barrett's esophagus in the United States
    Falk, GW
    Ours, TM
    Richter, JE
    [J]. GASTROINTESTINAL ENDOSCOPY, 2000, 52 (02) : 197 - 203
  • [10] Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue
    Galipeau, PC
    Prevo, LJ
    Sanchez, CA
    Longton, GM
    Reid, BJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (24) : 2087 - 2095